| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-40 |
| filingDate |
2004-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-05-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007512368-A |
| titleOfInvention |
Quinazolinone compounds as anticancer agents |
| abstract |
The present invention relates to quinazolinone compounds, pharmaceutically acceptable salts and prodrugs thereof; a pharmaceutically acceptable carrier and a quinazolinone compound, either alone or in combination with at least one additional therapeutic agent. It is related with the composition to contain. The invention also relates to methods of using the quinazolinone compounds either alone or in combination with at least one additional therapeutic agent as a KSP inhibitor in the treatment or prevention of proliferative disorders. One aspect of the present invention is useful in treating cell proliferative disorders. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016503805-A |
| priorityDate |
2003-11-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |